We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Clinigen Group Plc | LSE:CLIN | London | Ordinary Share | GB00B89J2419 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 925.00 | 924.50 | 925.00 | 0.00 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMCLIN
RNS Number : 0208H
Kryger Capital Limited
01 April 2022
FORM 8.3
PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY
A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
Rule 8.3 of the Takeover Code (the "Code")
1. KEY INFORMATION (a) Full name of discloser: Kryger Capital Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. ------------------------------ (c) Name of offeror/offeree in relation to whose relevant securities this form Clinigen Group plc (CLIN:LN) relates: Use a separate form for each offeror/offeree ------------------------------ (d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: ------------------------------ (e) Date position held/dealing undertaken: 31 March 2022 For an opening position disclosure, state the latest practicable date prior to the disclosure ------------------------------ (f) In addition to the company in 1(c) above, is the discloser making disclosures in NO respect of any other party to the offer? If it is a cash offer or possible cash offer, state "N/A" ------------------------------ 2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE
If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.
(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)
Class of relevant security: Interests Short positions ------------------ ------------------ Number % Number % ---------- ------------- --- (1) Relevant securities owned and/or controlled: 1,430,200 1.07% ---------- ------ ------------- --- (2) Cash-settled derivatives: ---------- ------ ------------- --- (3) Stock-settled derivatives (including options) and agreements to purchase/sell: ---------- ------ ------------- --- TOTAL: 1,430,200 1.07% ---------- ------ ------------- ---
All interests and all short positions should be disclosed.
Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).
(b) Rights to subscribe for new securities (including directors' and other employee options) Class of relevant security in relation to which subscription right exists: Details, including nature of the rights concerned and relevant percentages: 3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE
Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.
The currency of all prices and other monetary amounts should be stated.
(a) Purchases and sales Class of relevant security Purchase/sale Number of securities Price per unit ORDINARY Purchase 1,844 9.2425 GBP -------------- --------------------- --------------- ORDINARY Sale 14,474 9.2403 GBP -------------- --------------------- --------------- (b) Cash-settled derivative transactions Class of relevant Product description Nature of dealing Number of reference Price per unit security e.g. CFD e.g. opening/closing a securities long/short position, increasing/reducing a long/short position (c) Stock-settled derivative transactions (including options) (i) Writing, selling, purchasing or varying Class of Product Writing, Number of Exercise Type Expiry date Option money relevant description purchasing, securities price per e.g. paid/ security e.g. call selling, to which unit American, received per option varying etc. option European unit relates etc. (ii) Exercise Class of relevant Product description Exercising/ exercised Number of securities Exercise price per security e.g. call option against unit (d) Other dealings (including subscribing for new securities) Class of relevant security Nature of dealing Details Price per unit (if applicable) e.g. subscription, conversion 4. OTHER INFORMATION (a) Indemnity and other dealing arrangements Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none" N/a (b) Agreements, arrangements or understandings relating to options or derivatives Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state "none" N/a (c) Attachments Is a Supplemental Form 8 (Open Positions) attached? NO Date of disclosure: 01 April 2022 Contact name: Stephen Hill -------------- Telephone number*: 020 3910 7900 --------------
Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.
The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.
*If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel's Market Surveillance Unit. The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
RETFLFFSSLILIIF
(END) Dow Jones Newswires
April 01, 2022 10:25 ET (14:25 GMT)
1 Year Clinigen Chart |
1 Month Clinigen Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions